Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab (AK112) plus chemotherapy as induction for unresectable stage III NSCLC
ChiCTR2600122824Phase 2Recruiting
- Sponsor
- Shanghai Chest Hospital
- Start
- Apr 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ivonescimab in non-small cell lung cancer (NSCLC), sponsored by Shanghai Chest Hospital. Primary endpoint: Objective Response Rate (ORR). Started Apr 2026; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600122824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122824.